Fundraising FoxLumaCyte
Charlottesville, US · Founded 2012 · Delaware corporation · 2 known investors
Find your way into LumaCyte
Sign up to see every warm intro you have to LumaCyte
- Paths you didn't know you had: your email and LinkedIn already hold routes to the LumaCyte team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Early commercial stage company selling a real-time cell analyzer to pharma companies.
Founders & leadership
LumaCyte was founded in 2012 by Sean Hart.
SH
Sean HartFounder · Chief Executive Officer & Chief Scientific OfficerSean Hart founded LumaCyte in 2012 to commercialize label-free single-cell analysis technologies developed during his 12-year tenure as a research scientist at the Naval Research Laboratory. He holds a Ph.D. in Chemistry from Tufts University and has authored numerous peer-reviewed publications and patents in cell analysis, optical engineering, and bioanalytical instrumentation.
RH
Renee HartNamed on SEC filing
RH
Robert HeiserNamed on SEC filing
PB
Pete BuzyNamed on SEC filing
DW
Dennis WalczewskiNamed on SEC filing
PM
Paul MeisterNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$21.1M disclosed across 8 rounds · 2014–2023
▶$10MraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul MeisterDirector
- Dennis WalczewskiDirector
- Sean HartExecutive Officer, Director
- Robert HeiserDirector
- Renee HartExecutive Officer, Director
- Offering amount
- $13M
- Amount sold
- $10M
- Sales commissions
- $600K
- Proceeds to insiders
- $2.8M
- Placement agents
- EuroConsult Capital LLC
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedMay 2022 · 6 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMay 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hart ReneeExecutive Officer
- Sean HartExecutive Officer
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$750KraisedMay 2022 · 1 investors · BiotechnologyRule 506(b)
▶$750KraisedMay 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Renee HartExecutive Officer
- Sean HartExecutive Officer
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Renee HartExecutive Officer
- Sean HartExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$550KraisedMay 2022 · 3 investors · BiotechnologyRule 506(b)
▶$550KraisedMay 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean HartExecutive Officer
- Renee HartExecutive Officer
- Offering amount
- $550K
- Amount sold
- $550K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$525KraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
▶$525KraisedMay 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Renee HartExecutive Officer
- Sean HartExecutive Officer
- Offering amount
- $525K
- Amount sold
- $525K
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.8MraisedMar 2022 · 3 investors · BiotechnologyRule 506(b)
▶$6.8MraisedMar 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Renee HartExecutive Officer, Director
- Robert HeiserDirector
- Pete BuzyDirector
- Sean HartExecutive Officer, Director
- Dennis WalczewskiDirector
- Paul MeisterDirector
- Offering amount
- $9.3M
- Amount sold
- $6.8M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30.1KraisedMay 2014 · 1 investors · BiotechnologyRule 506(b)
▶$30.1KraisedMay 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean Jeffrey HartExecutive Officer
- Renee Adele HartDirector
- Offering amount
- $2M
- Amount sold
- $30.1K
- Minimum investment
- $10K
- Proceeds to insiders
- $100K
- Placement agents
- Janet and Kenneth Jones
- First sale
- Apr 2014
- Incorporated
- Limited Liability Company, Virginia, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does LumaCyte do?
- Early commercial stage company selling a real-time cell analyzer to pharma companies.
- Who founded LumaCyte?
- LumaCyte was founded by Sean Hart in 2012.
- Who are LumaCyte's investors?
- LumaCyte's investors include Asahi Kasei Corporate Venture Capital, Novalis LifeSciences.
- How much funding has LumaCyte raised?
- LumaCyte has disclosed $21.1M raised across 8 rounds.
- Where is LumaCyte headquartered?
- LumaCyte is headquartered in Charlottesville, US.